La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

H. Lundbeck Performance dei guadagni passati

Il passato criteri di controllo 2/6

Gli utili di H. Lundbeck sono diminuiti a un tasso medio annuo di -4.6%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 8.9%. I ricavi sono cresciuti crescere a un tasso medio annuo di 2.7%. Il ritorno sul capitale proprio di H. Lundbeck è 10.8% e ha margini netti di 12%.

Informazioni chiave

-4.6%

Tasso di crescita degli utili

-4.6%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	12.4%
Tasso di crescita dei ricavi	2.7%
Rendimento del capitale proprio	10.8%
Margine netto	12.0%
Prossimo aggiornamento sui guadagni	21 Aug 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

Ripartizione dei ricavi e delle spese

Come H. Lundbeck guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

CPSE:HLUN B Ricavi, spese e utili (DKK Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
31 Mar 24	20,156	2,416	8,823	3,571
31 Dec 23	19,912	2,290	8,706	3,457
30 Sep 23	19,614	2,467	8,426	3,386
30 Jun 23	19,381	2,479	8,248	3,476
31 Mar 23	18,918	2,384	8,082	3,617
31 Dec 22	18,246	1,916	7,689	3,754
30 Sep 22	17,619	1,603	7,398	3,846
30 Jun 22	16,913	1,236	7,127	3,947
31 Mar 22	16,398	1,109	6,768	3,884
31 Dec 21	16,299	1,318	6,625	3,820
30 Sep 21	16,521	1,873	6,698	3,711
30 Jun 21	16,971	1,965	6,680	3,655
31 Mar 21	17,381	2,110	6,720	2,999
31 Dec 20	17,672	1,581	6,912	3,753
30 Sep 20	17,818	904	6,812	3,760
30 Jun 20	17,490	1,242	6,744	3,538
31 Mar 20	17,366	1,507	6,672	4,039
31 Dec 19	17,036	2,313	6,413	3,116
30 Sep 19	16,811	3,091	6,212	3,214
30 Jun 19	17,309	3,395	6,143	3,302
31 Mar 19	17,766	3,606	6,061	3,313
31 Dec 18	18,117	3,907	6,039	3,277
30 Sep 18	18,313	3,806	6,120	3,069
30 Jun 18	18,028	3,627	6,174	2,903
31 Mar 18	17,608	3,236	6,298	2,765
31 Dec 17	17,234	2,624	6,482	2,705
30 Sep 17	17,007	2,544	6,428	2,769
30 Jun 17	16,607	1,988	6,462	2,839
31 Mar 17	16,075	1,612	6,424	2,887
31 Dec 16	15,634	1,211	6,293	2,967
30 Sep 16	15,202	290	6,475	-1,979
30 Jun 16	14,923	-1,289	7,320	3,196
31 Mar 16	14,801	-5,427	7,573	3,095
31 Dec 15	14,594	-5,694	7,762	3,097
30 Sep 15	14,108	-5,879	7,814	8,003
30 Jun 15	13,625	-4,615	6,928	2,666
31 Mar 15	13,444	-565	6,581	2,790
31 Dec 14	13,468	-153	6,298	2,689
30 Sep 14	13,808	503	6,208	2,670
30 Jun 14	14,181	765	6,147	2,782
31 Mar 14	14,269	119	6,814	2,807
31 Dec 13	15,258	855	6,749	2,834
30 Sep 13	15,516	1,036	6,692	2,905

Guadagni di qualità: HLUN B ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di HLUN B (12%) sono inferiori rispetto allo scorso anno (12.6%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di HLUN B sono diminuiti del 4.6% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di HLUN B nell'ultimo anno ( 1.3% ) supera la media quinquennale ( -4.6% all'anno).

Guadagni vs Settore: La crescita degli utili HLUN B nell'ultimo anno ( 1.3% ) non ha superato quella del settore Pharmaceuticals 4.5%.

H. Lundbeck Performance dei guadagni passati

Il passato criteri di controllo 2/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

Recent updates

Investors Interested In H. Lundbeck A/S' (CPH:HLUN B) Earnings

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate